TY - JOUR
T1 - Multidisciplinary approach to treating complex immune dysregulation disorders
T2 - an adaptive model for institutional implementation
AU - Henderson, Lauren A.
AU - Abraham, Roshini S.
AU - Ahmed, Aisha
AU - Blount, Lindsey
AU - Canna, Scott W.
AU - Chaimowitz, Natalia S.
AU - Chandrakasan, Shanmuganathan
AU - Coates, Bria
AU - Connelly, James A.
AU - Cooper, Megan A.
AU - Duncan, Christine N.
AU - French, Anthony
AU - Hazen, Melissa
AU - Hermiston, Michelle L.
AU - Nolan, Brian
AU - Ray, Anish
AU - Rose, Melissa J.
AU - Satter, Lisa Forbes
AU - Schulert, Grant
AU - Tejtel, Sara Kristen Sexson
AU - Vogel, Tiphanie
AU - Walkovich, Kelly
AU - Zinter, Matt S.
AU - Behrens, Edward M.
N1 - Publisher Copyright:
Copyright © 2025 Henderson, Abraham, Ahmed, Blount, Canna, Chaimowitz, Chandrakasan, Coates, Connelly, Cooper, Duncan, French, Hazen, Hermiston, Nolan, Ray, Rose, Satter, Schulert, Tejtel, Vogel, Walkovich, Zinter and Behrens.
PY - 2025
Y1 - 2025
N2 - Patients with immune dysregulation may present with varying combinations of autoimmunity, autoinflammation, immunodeficiency, atopy, lymphoproliferation, and/or malignancy, often with multisystem involvement. Recognizing specific patterns of immune dysregulation, coordinating and interpreting complex diagnostic testing, and choosing initial (often empiric) treatment can be challenging. Centers are increasingly assembling multidisciplinary teams (MDTs) to standardize evaluation and optimize treatment of patients with complex immune dysregulation (immune dysregulation MDTs [immMDTs]). However, published information on the composition and function of immMDTs is sparse, and there is little guidance for those seeking to establish or optimize an immMDT. To inform this review, we assembled a panel of 24 pediatric providers from multiple specialties who actively participate in immMDTs to provide expert opinion. We also conducted a search of the available information on pediatric immMDTs from PubMed. Based on these insights, we summarize the structure and function of active immMDTs across the United States and focus on best practices and context-dependent solutions that may enable institutions with varying goals, patient populations, and resources to establish an immMDT.
AB - Patients with immune dysregulation may present with varying combinations of autoimmunity, autoinflammation, immunodeficiency, atopy, lymphoproliferation, and/or malignancy, often with multisystem involvement. Recognizing specific patterns of immune dysregulation, coordinating and interpreting complex diagnostic testing, and choosing initial (often empiric) treatment can be challenging. Centers are increasingly assembling multidisciplinary teams (MDTs) to standardize evaluation and optimize treatment of patients with complex immune dysregulation (immune dysregulation MDTs [immMDTs]). However, published information on the composition and function of immMDTs is sparse, and there is little guidance for those seeking to establish or optimize an immMDT. To inform this review, we assembled a panel of 24 pediatric providers from multiple specialties who actively participate in immMDTs to provide expert opinion. We also conducted a search of the available information on pediatric immMDTs from PubMed. Based on these insights, we summarize the structure and function of active immMDTs across the United States and focus on best practices and context-dependent solutions that may enable institutions with varying goals, patient populations, and resources to establish an immMDT.
KW - collaborative management
KW - hemophagocytic lymphohistiocytosis
KW - immune dysregulation
KW - institutional implementation
KW - multidisciplinary teams
KW - quality improvement research
UR - https://www.scopus.com/pages/publications/105000762029
U2 - 10.3389/fimmu.2025.1519955
DO - 10.3389/fimmu.2025.1519955
M3 - Review article
C2 - 40124385
AN - SCOPUS:105000762029
SN - 1664-3224
VL - 16
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 1519955
ER -